Skip to content
value.today
Precision Biosciences Inc. logo

Precision Biosciences Inc.

Total raised
$114 M
2 rounds on record
Latest round
$88 M
May 2018
First round on record
Apr 2015
Today
Went public
See the company page

Precision Biosciences Inc. is listed today as Precision BioSciences, Inc.: market value, financials and filings are on its company page.

Funding rounds

2 counted as startup funding. Open the number of investors for the round's details.

Funding rounds of Precision Biosciences Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
May 2018$88 MNo. 2$50 to $250 million

Precision Biosciences Inc.: Raise no. 2, May 2018

Investors in this round

40 investors had bought by the notice of Jun 8, 2018: 40 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 5 investors are named for Precision Biosciences Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$88 M of $110 M offered; $22 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Abid Ansari · Executive Officer
  • Derek Jantz · Executive Officer, Director
  • Jeff Smith · Executive Officer
  • Matthew Kane · Executive Officer, Director
  • Robert Adelman · Director
  • Tony Yao · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On the use of proceeds: “None other than payments of salary in the ordinary course of business.”

Signed by Michael P. Saber, Attorney-in-Fact. Source: SEC Form D, newest notice filed Jun 8, 2018. Read the notice at the SEC.

equitySEC
Apr 2015$26 MNo. 1$10 to $50 million

Precision Biosciences Inc.: Raise no. 1, Apr 2015

Investors in this round

11 investors had bought by the notice of May 12, 2015: 11 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 5 investors are named for Precision Biosciences Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$26 M of $26 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Derek Jantz · Executive Officer, Director
  • Jeff Smith · Executive Officer
  • Matthew Kane · Executive Officer, Director
  • Todd Melby · Executive Officer
  • Ben Auspitz · Director
  • Robert Adelman · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On the use of proceeds: “Excluding salaries paid in the ordinary course of business.”

Signed by Michael P. Saber, Attorney-in-Fact. Source: SEC Form D, newest notice filed May 12, 2015. Read the notice at the SEC.

equitySEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • As the listed company Precision BioSciences, Inc., its revenue in fiscal 2025 came from these business segments: Operating $34.26 million (100%).

    Annual report (SEC XBRL) · Dec 2025

  • Precision Biosciences Inc. chose not to state its revenue in its newest notice of a funding round (Jun 2018).

    SEC Form D · Jun 2018

  • The industry group it chose in its notices: Biotechnology.

    SEC Form D · Jun 2018

Products and services#

No products or services of Precision Biosciences Inc. are on record.

Investors#

5 named in official filings. Open an investor to see everything it has backed.

Investors in Precision Biosciences Inc.
InvestorKindAmountRoundRoleSource
Fmr LLCFund or asset managernot statednot statedHeld Series A and B preferred stock, 10% owner (Form 3, 2019)SEC Form 3
venBio Global Strategic Fund, L.P.Fund or asset managernot statednot statedHeld Series A and B preferred stock, 10% owner, director (Form 3, 2019)SEC Form 3
venBio Global Strategic GP, L.P.Fund or asset managernot statednot statedHeld Series A and B preferred stock, 10% owner (Form 3, 2019)SEC Form 3
venBio Global Strategic GP, Ltd.Companynot statednot statedHeld Series A and B preferred stock, 10% owner (Form 3, 2019)SEC Form 3
Yao Tony Dung LingPersonnot statednot statedHeld Series B preferred stock, director (Form 3, 2019)SEC Form 3

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 2 rounds above had up to 40 investors.

Largest shareholders today

Institutions holding Precision BioSciences, Inc. shares, as of Sep 30, 2026.

Source: SEC Form 13F holdings reports · as of Sep 30, 2026. Value held and share of the company. All holders are on the company page.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by Precision Biosciences Inc.
NameRoleNamed in
Abid AnsariExecutive officerJun 2018
Derek JantzExecutive officerJun 2018
Jeff SmithExecutive officerJun 2018
Matthew KaneExecutive officerJun 2018
Todd MelbyExecutive officerMay 2015
Derek JantzDirectorJun 2018
Matthew KaneDirectorJun 2018
Robert AdelmanDirectorJun 2018
Tony YaoDirectorJun 2018
Ben AuspitzDirectorMay 2015

Went public since 2019. Its SEC number is that of a company listed on a stock exchange.